Non-Invasive Prenatal Testing (NIPT) Market Research Report Information By Product Type (Devices, Consumables), Techniques (Biochemical Screening Tests, Ultrasound Detection), Application (Trisomy, Microdeletion syndrome) and End-User (Diagnostic Laboratories, Hospitals, cell DNA screening) - Forecast to 2030

Non-Invasive Prenatal Testing (NIPT) Market Overview

The Non-Invasive Prenatal Testing Market is expected to reach USD 11.3 Billion by 2030 at 13.1% CAGR during the forecast period 2022-2030.

Worldwide demand for NIPT is rising due to several factors, including a rise in doctors' preferences for sophisticated genetic screening for high-risk pregnancies, an eagerness to put off having children, and a boom in pregnancy-related problems in the last or second trimester. The devastating effect of COVID-19 has been unexpected and catastrophic worldwide, and NIPT has not seen any change regarding demand across all regions due to the pandemic. When the pandemic is finished, this market's demand and growth will resume to pre-pandemic levels, which will explain the increase in CAGR. A child's chance of developing genetic defects increases when genes and chromosomes mutate. According to reports, trisomy 21 is one of the most prevalent chromosomal disorders, affecting about 5,000 newborns annually in the United States.

The demand for an efficient screening tool for prenatal tests has increased due to the rising prevalence of chromosomal defects. Amniocentesis and chorionic villus sampling are invasive prenatal testing methods that might result in complications like miscarriage. As a result, there is a significant need for more effective, non-invasive, and safe tests and a fall in using these procedures. NIPT can be used to detect common trisomies in the fetus, such as Down syndrome, fetal rhesus D status, Turner syndrome, and sex chromosomal problems, as well as to determine the fetal sex. This is done using cell-free fetal DNA (cffDNA), which circulates in the mother's blood. Significant technological developments are being made in the sector to enhance testing capabilities. Many well-known companies and fresh start-ups seek financing for NIPT technique development and clinical testing. Government and business organizations are searching for research facilities and start-ups to provide cutting-edge testing methods to identify important genetic abnormalities through NIPT. Many nations have adopted rules that make non-invasive prenatal diagnostics the norm for prenatal screening rather than invasive examinations.

NIPT is the testing procedure done during the pregnancy period to monitor the fetal growth and related diagnosis. Annually it is predicted that around 21 million girls aged 15 to 19 years give birth in developing regions around the globe.

Thus, it is among the reasons why NIPT is needed for safe delivery of the baby.  

The birth rate is expected to increase during the forecast period.

Market Influencer

Rising cases of premature pregnancy in developing and underdeveloped countries.

Non-Invasive Prenatal Testing (NIPT) Market Trends

• Growing global population.


• Adoption of unhealthy lifestyle habits during pregnancy.


• Rising awareness of non-invasive prenatal testing.

• Availability of alternative techniques for prenatal testing.


• Less accuracy of non-invasive prenatal testing compared to the invasive prenatal testing.

Non-Invasive Prenatal Testing (NIPT) Market Segmentation

Non-Invasive Prenatal Testing (NIPT) Product Outlook

The Non-Invasive Prenatal Testing (NIPT) Market based on product type is broadly segmented into devices, consumables, and others.

• Devices: This segment is further sub-segmented into ultrasound devices, polymerase chain reaction instruments, microarrays, sequencing systems, and others. Ultrasound devices are generally known as a sonogram. They use the ultrasound frequency for imaging of the fetal in pregnant women. Polymerase chain reaction instruments are used to amplify the DNA sequence for the analysis of any genetic issues related to pregnant women. Microarray is used to determine the levels of genes. It helps understand the conditions and plan the treatment accordingly. Sequencing systems are automated devices used for sequencing the DNA. It helps in the identification of the genomes. Other devices include fetal doppler machine and neonatal stress testers.


• Consumables: It segment is further segmented into assay kits & reagents, disposables, and others. Assay kits & reagents comprise of ultrasound transmission gel, cleaning solution, and others. The disposables comprises of swipes, cottons, hand gloves, ad others.


• Others: Other consumable comprises ultrasound transducers, probes, printers, related services, and others.

Non-Invasive Prenatal Testing (NIPT) Techniques Outlook

The non-Invasive prenatal testing (NIPT) market based on technique is segmented into biochemical screening tests and ultrasound detection.

• Biochemical Screening Tests: It is used for down syndrome, aneuploidies, and other genetic disorders. The test depends mainly on evaluating hormones and other proteins produced by the placenta.

• Ultrasound Detection: This is the most preferred and utilized technique for In this method, the ultrasound machine is used. This machine provides 2D image of the fetal. The machine uses high-frequency sound waves and their echoes. During the testing the sound pulses frequencies of the range 1 to 5 megahertz is transmitted into the body using a probe. The probe also acts as a receiver for the sound waves that are reflected from tissue surfaces.

Non-Invasive Prenatal Testing (NIPT) Application Outlook

• Trisomy: It is a genetic disorder with three copies of a chromosome instead of two. There are different types of trisomy, such as down syndrome, Edward syndrome, Patau syndrome, and others. NIPT helps in identifying and planning the possible treatment as per the results.


• Microdeletion syndrome: It is a genetic disorder caused by a deletion of several genes on a certain chromosome.


• Others: It includes pregnancy screening to monitor fetal growth. It is mostly used for non-invasive testing. It also helps in imaging the fetal in its development phases and helps in maintaining the health of the fetal as well as the patient.

Non-Invasive Prenatal Testing (NIPT) End-User Outlook

• Diagnostic Laboratories: Diagnostic laboratories are the testing setting where the NIPT test is been carried out. The labs provide various NIPT testing services as per the requirement of the patients. The diagnostic laboratories are largest segment owing to a large number of diagnostic labs/centers that provides NIPT testing products and services.


• Hospitals: Hospitals play a very important role in prenatal testing. It provides in house testing facility to in-house patients. It helps in prompt testing of the pregnant patient that helps accurate treatments as per the diagnoses.


• Research Institutes: Research and developments are being done by various institutes. Studies such as free cell DNA screening are also carried out. For instance, Mayo Foundation for Medical Education and Research has published various research articles about the free cell DNA screening. This indicates that there is a potential for research and development in NIPT marketing.

Non-Invasive Prenatal Testing (NIPT) Market By Region

• Americas: America is the fastest-growing region owing to technological advancements in NIPT.

• Europe: In Europe, regulatory agencies are active towards NIPT related activities which is supporting the market growth in respective regions.

• Asia-Pacific: This is the fastest-growing non-Invasive prenatal testing (NIPT) market on account of the increasing population in China and India which is approximately 1,389.61 million and about 1,311.55 million, respectively, in 2019.

• Middle East & Africa: This region has a low share is owing to the limited technological development, restricting the growth of the non-Invasive prenatal testing (NIPT) market.

Non-Invasive Prenatal Testing (NIPT) Market Key Players

• Illumina, Inc. (US)


• Thermo Fisher Scientific, Inc. (US)


• 
  General Electric Company [GE Healthcare] (US)


• Perkinelmer, Inc. (US)


• Agilent Technologies, Inc. (US)


• Beijing Genomics Institute (China)


• Hoffman-La Roche Ltd. (Switzerland)


• Tarsa Therapeutics, Inc. (US)


• PhytoHealth Corporation (Taiwan)


• 
  Laboratory Corporation of America Holdings (US)


• Natera, Inc. (US)


• Yourgene Health (UK)


• Centogene Holding AG [CENTOGENE AG ] (Germany)